PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
CRH plc (CRH)
114.271.68 (1.49%)
111.48 - 114.40
76.75 - 114.40
5.09M / 4.23M (Avg.)
23.96 | 4.77
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-100.00%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-100.00%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-354.73%
Negative EBIT growth while JHX is at 386.17%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-354.73%
Negative operating income growth while JHX is at 123.19%. Joel Greenblatt would press for urgent turnaround measures.
26.79%
Net income growth at 50-75% of JHX's 43.58%. Martin Whitman would question fundamental disadvantages in expenses or demand.
-100.00%
Negative EPS growth while JHX is at 50.00%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-100.00%
Negative diluted EPS growth while JHX is at 51.06%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-100.00%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-100.00%
Reduced diluted shares while JHX is at 0.12%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 10Y revenue/share CAGR while JHX stands at 117.83%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-100.00%
Negative 5Y CAGR while JHX stands at 48.10%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-100.00%
Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative equity/share CAGR over 10 years while JHX stands at 756.53%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-100.00%
Negative 5Y equity/share growth while JHX is at 116.49%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-100.00%
Negative 3Y equity/share growth while JHX is at 75.99%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.